Abbott’s Investigational Treatment for Advanced Parkinson’s Disease Demonstrates Positive Results in Phase 3 Clinical Trial

Share

Statistically Significant Improvements in 'Off' Time Over Standard Oral Treatment; Data to Be Presented at American Academy of Neurology Annual Meeting

ABBOTT PARK, Ill., April 17, 2012 — Abbott announced today the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel (LCIG). The study showed that patients treated with LCIG for 12 weeks reported clinically meaningful and statistically significant improvements in "off" time compared to levodopa-carbidopa immediate release (IR) tablets, without increasing troublesome dyskinesia. “Off” time refers to the periods of poor mobility, slowness and stiffness experienced by patients with Parkinson's disease. The results from the study will be presented as part of the Emerging Science program (formerly known as Late-Breaking) at the American Academy of Neurology's 64th Annual Meeting in New Orleans on April 25. Click here to read Abbott’s press release.

Click for a printer friendly version

Back to top